KR101612642B1 - 테노포비어 알라펜아미드 헤미푸마레이트 - Google Patents

테노포비어 알라펜아미드 헤미푸마레이트 Download PDF

Info

Publication number
KR101612642B1
KR101612642B1 KR1020147003886A KR20147003886A KR101612642B1 KR 101612642 B1 KR101612642 B1 KR 101612642B1 KR 1020147003886 A KR1020147003886 A KR 1020147003886A KR 20147003886 A KR20147003886 A KR 20147003886A KR 101612642 B1 KR101612642 B1 KR 101612642B1
Authority
KR
South Korea
Prior art keywords
hemifumarate
delete delete
tenofovir
composition
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147003886A
Other languages
English (en)
Korean (ko)
Other versions
KR20140054068A (ko
Inventor
다즈한 리우
빙 쉬
팡 왕
리차드 훙 치우 유
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46785793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101612642(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20140054068A publication Critical patent/KR20140054068A/ko
Application granted granted Critical
Publication of KR101612642B1 publication Critical patent/KR101612642B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020147003886A 2011-08-16 2012-08-15 테노포비어 알라펜아미드 헤미푸마레이트 Active KR101612642B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524224P 2011-08-16 2011-08-16
US61/524,224 2011-08-16
PCT/US2012/050920 WO2013025788A1 (en) 2011-08-16 2012-08-15 Tenofovir alafenamide hemifumarate

Publications (2)

Publication Number Publication Date
KR20140054068A KR20140054068A (ko) 2014-05-08
KR101612642B1 true KR101612642B1 (ko) 2016-04-14

Family

ID=46785793

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147003886A Active KR101612642B1 (ko) 2011-08-16 2012-08-15 테노포비어 알라펜아미드 헤미푸마레이트

Country Status (41)

Country Link
US (2) US8754065B2 (cg-RX-API-DMAC7.html)
EP (3) EP3831832A1 (cg-RX-API-DMAC7.html)
JP (5) JP5651275B2 (cg-RX-API-DMAC7.html)
KR (1) KR101612642B1 (cg-RX-API-DMAC7.html)
CN (2) CN110343135A (cg-RX-API-DMAC7.html)
AP (1) AP3639A (cg-RX-API-DMAC7.html)
AR (1) AR087546A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012296622C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014003420B1 (cg-RX-API-DMAC7.html)
CA (1) CA2845553C (cg-RX-API-DMAC7.html)
CL (1) CL2014000370A1 (cg-RX-API-DMAC7.html)
CO (1) CO6880063A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140072A (cg-RX-API-DMAC7.html)
CY (1) CY1118385T1 (cg-RX-API-DMAC7.html)
DK (1) DK2744810T4 (cg-RX-API-DMAC7.html)
EA (1) EA027768B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14013206A (cg-RX-API-DMAC7.html)
ES (1) ES2608871T5 (cg-RX-API-DMAC7.html)
FI (1) FI2744810T4 (cg-RX-API-DMAC7.html)
HR (1) HRP20161696T4 (cg-RX-API-DMAC7.html)
HU (1) HUE031253T2 (cg-RX-API-DMAC7.html)
IL (2) IL230949A (cg-RX-API-DMAC7.html)
IN (1) IN2014DN01012A (cg-RX-API-DMAC7.html)
LT (1) LT2744810T (cg-RX-API-DMAC7.html)
MA (1) MA35350B1 (cg-RX-API-DMAC7.html)
MD (1) MD4508C1 (cg-RX-API-DMAC7.html)
ME (1) ME02612B (cg-RX-API-DMAC7.html)
MX (1) MX336627B (cg-RX-API-DMAC7.html)
PE (1) PE20141328A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500349A1 (cg-RX-API-DMAC7.html)
PL (1) PL2744810T5 (cg-RX-API-DMAC7.html)
PT (1) PT2744810T (cg-RX-API-DMAC7.html)
RS (1) RS55353B2 (cg-RX-API-DMAC7.html)
SG (1) SG2014011548A (cg-RX-API-DMAC7.html)
SI (1) SI2744810T2 (cg-RX-API-DMAC7.html)
SM (2) SMT201600476T1 (cg-RX-API-DMAC7.html)
TW (1) TWI516499B (cg-RX-API-DMAC7.html)
UA (1) UA115311C2 (cg-RX-API-DMAC7.html)
UY (1) UY34262A (cg-RX-API-DMAC7.html)
WO (1) WO2013025788A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201400582B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3639A (en) 2011-08-16 2016-03-13 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
ES2661705T3 (es) 2011-10-07 2018-04-03 Gilead Sciences, Inc. Métodos para la preparación de análogos de nucleótidos antivirales
WO2013116730A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2015040640A2 (en) * 2013-09-20 2015-03-26 Laurus Labs Private Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
CN108148094A (zh) * 2014-11-12 2018-06-12 四川海思科制药有限公司 一种替诺福韦艾拉酚胺富马酸盐晶型c及其制备方法和用途
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2015373104B2 (en) * 2015-01-03 2020-07-09 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
CN105669751B (zh) * 2015-03-05 2018-09-21 洛阳聚慧医药科技有限公司 非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
WO2016205141A1 (en) * 2015-06-17 2016-12-22 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
EP4233846B1 (en) 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
WO2017007701A1 (en) * 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
WO2017027434A1 (en) 2015-08-10 2017-02-16 Merck Sharp & Dohme Corp. Antiviral beta-amino acid ester phosphodiamide compounds
WO2017037608A1 (en) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
CN106699812A (zh) * 2015-11-12 2017-05-24 江苏豪森药业集团有限公司 替诺福韦前药的制备和纯化方法
WO2017100108A1 (en) 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
ES2806604T3 (es) 2016-02-02 2021-02-18 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017203395A1 (en) * 2016-05-21 2017-11-30 Shilpa Medicare Limited Crystalline forms of tenofovir alafenamide hemi fumarate
WO2017211325A1 (zh) * 2016-06-05 2017-12-14 上海诚妙医药科技有限公司 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
WO2018039157A1 (en) 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN107793451A (zh) * 2016-08-30 2018-03-13 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺半富马酸盐化合物及其药物组合物
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
CN113072583A (zh) * 2016-11-28 2021-07-06 正大天晴药业集团股份有限公司 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
EP3558322B1 (en) * 2016-12-22 2021-09-29 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
KR20190100250A (ko) 2016-12-22 2019-08-28 머크 샤프 앤드 돔 코포레이션 테노포비르의 항바이러스 지방족 에스테르 전구약물
WO2018115046A1 (en) 2016-12-23 2018-06-28 Sandoz Ag Crystalline solid forms of tenofovir alafenamide
US10899786B2 (en) 2016-12-23 2021-01-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
TWI714820B (zh) 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (en) 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
CN107445994A (zh) * 2017-05-31 2017-12-08 北京阜康仁生物制药科技有限公司 替诺福韦艾拉酚胺半富马酸盐新晶型
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107865874A (zh) * 2017-10-23 2018-04-03 上海博悦生物科技有限公司 一种替诺福韦艾拉酚胺的药物组合物及其制备方法
EP3700573A1 (en) 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
WO2019130354A1 (en) * 2017-12-30 2019-07-04 Cipla Limited Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
CN108440596B (zh) * 2018-03-22 2020-07-03 科兴生物制药股份有限公司 一种半富马酸替诺福韦艾拉酚胺的新型制备工艺
EP3808752A4 (en) 2018-06-12 2022-03-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PHOSPHONYMIDE ESTER COMPOUND, SALT THEREOF, RELATIVE CRYSTAL FORM THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP3823629B1 (en) 2018-07-19 2024-12-25 Merck Sharp & Dohme LLC Phosphinic amide prodrugs of tenofovir
US20210393631A1 (en) 2018-09-19 2021-12-23 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
KR102054104B1 (ko) * 2019-04-30 2019-12-09 유니셀랩 주식회사 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) * 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN110452268A (zh) * 2019-08-21 2019-11-15 天地恒一制药股份有限公司 一种丙酚替诺福韦半富马酸单晶的制备方法
CA3157275C (en) 2019-11-26 2026-02-10 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
EP4085062A1 (en) 2020-02-20 2022-11-09 Cipla Limited Novel salts and/or co-crystals of tenofovir alafenamide
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
FI4440702T3 (fi) 2021-12-03 2025-08-08 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
AU2022403012B2 (en) 2021-12-03 2026-02-12 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
AU2022399845B2 (en) 2021-12-03 2026-03-26 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
CN119768183A (zh) 2022-08-26 2025-04-04 吉利德科学公司 用于广泛中和抗体的给药和安排方案
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
EP4698174A1 (en) 2023-04-19 2026-02-25 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
WO2024249573A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
CN122295099A (zh) 2023-07-28 2026-06-26 吉利德科学公司 用于治疗和预防hiv的来那卡帕韦的每周方案
AU2023462614A1 (en) 2023-08-23 2026-03-19 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
KR20260093341A (ko) 2023-10-11 2026-06-19 길리애드 사이언시즈, 인코포레이티드 가교 트리시클릭 카르바모일피리돈 화합물 및 이의 용도
AU2024360779A1 (en) 2023-10-11 2026-04-16 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
IL327206A (en) 2023-10-11 2026-05-01 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their uses
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2026076265A1 (en) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008241A2 (en) 2000-07-21 2002-01-31 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
WO2008143500A1 (en) 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Tenofovir disoproxil hemi-fumaric acid co-crystal

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5468768A (en) 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
DK0915894T3 (da) 1996-07-26 2003-09-15 Gilead Sciences Inc Nukleotidanaloger
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
WO1998004569A1 (en) 1996-07-26 1998-02-05 Gilead Sciences, Inc. Nucleotide analogs
PT1243590E (pt) 1997-07-25 2005-05-31 Gilead Sciences Inc Composicao de analogos nuclotidicos e metodo de sintese
TWI275392B (en) 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
JP2004288898A (ja) * 2003-03-24 2004-10-14 Canon Inc 太陽電池モジュールの製造方法
ECSP045074A (es) 2004-04-22 2004-05-28 Inhibidores hidroxipirimidinona carboxamida n-sustituida de integrasa de vih
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
WO2007013086A1 (en) 2005-07-26 2007-02-01 Hetero Drugs Limited Novel polymorphs of tenofovir disoproxil fumarate
KR101477822B1 (ko) 2006-07-07 2015-01-02 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
EP2046792B1 (en) * 2006-07-12 2015-02-25 Mylan Laboratories Limited Process for the preparation of tenofovir
PT3150586T (pt) 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
PL2393485T3 (pl) 2009-02-06 2015-12-31 Gilead Sciences Inc Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
AP3639A (en) 2011-08-16 2016-03-13 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
ES2661705T3 (es) 2011-10-07 2018-04-03 Gilead Sciences, Inc. Métodos para la preparación de análogos de nucleótidos antivirales
WO2013116730A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008241A2 (en) 2000-07-21 2002-01-31 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US7390791B2 (en) 2000-07-21 2008-06-24 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues
WO2008143500A1 (en) 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Tenofovir disoproxil hemi-fumaric acid co-crystal

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
DK2744810T4 (da) 2023-11-20
IL230949A (en) 2015-09-24
US9296769B2 (en) 2016-03-29
CY1118385T1 (el) 2017-06-28
NZ620421A (en) 2015-05-29
IL230949A0 (en) 2014-03-31
EP2744810B2 (en) 2023-09-13
ES2608871T3 (es) 2017-04-17
DK2744810T3 (en) 2016-12-05
TWI516499B (zh) 2016-01-11
UA115311C2 (uk) 2017-10-25
ECSP14013206A (es) 2014-03-31
FI2744810T4 (fi) 2023-11-22
JP5651275B2 (ja) 2015-01-07
JP2015038149A (ja) 2015-02-26
HRP20161696T1 (hr) 2017-02-24
EA027768B1 (ru) 2017-08-31
EP2744810A1 (en) 2014-06-25
EP3831832A1 (en) 2021-06-09
SG2014011548A (en) 2014-09-26
HK1199026A1 (en) 2015-06-19
CA2845553C (en) 2019-05-28
CA2845553A1 (en) 2013-02-21
AP2014007437A0 (en) 2014-02-28
JP5956537B2 (ja) 2016-07-27
PL2744810T5 (pl) 2024-02-05
SI2744810T2 (sl) 2023-11-30
RS55353B1 (sr) 2017-03-31
AU2012296622B2 (en) 2014-09-11
HUE031253T2 (en) 2017-07-28
US8754065B2 (en) 2014-06-17
MA35350B1 (fr) 2014-08-01
ME02612B (me) 2017-06-20
ES2608871T5 (es) 2024-04-04
SMT201600476T1 (it) 2017-03-08
PH12014500349A1 (en) 2016-04-06
AR087546A1 (es) 2014-04-03
PE20141328A1 (es) 2014-10-04
AU2012296622C1 (en) 2017-02-16
US20130065856A1 (en) 2013-03-14
RS55353B2 (sr) 2023-11-30
UY34262A (es) 2013-04-05
IL240649A0 (en) 2015-09-24
JP2016169228A (ja) 2016-09-23
CL2014000370A1 (es) 2014-09-05
PT2744810T (pt) 2016-11-04
AP3639A (en) 2016-03-13
MD4508B1 (ro) 2017-08-31
SMT201600476B (it) 2017-03-08
EP3070088A1 (en) 2016-09-21
IN2014DN01012A (cg-RX-API-DMAC7.html) 2015-05-15
CR20140072A (es) 2014-06-19
JP6280162B2 (ja) 2018-02-14
HRP20161696T4 (hr) 2023-10-13
US20140187773A1 (en) 2014-07-03
JP2014528924A (ja) 2014-10-30
MD20140011A2 (en) 2014-05-31
MX2014001549A (es) 2014-02-27
SI2744810T1 (sl) 2017-01-31
TW201321396A (zh) 2013-06-01
EP2744810B1 (en) 2016-10-05
KR20140054068A (ko) 2014-05-08
PL2744810T3 (pl) 2017-04-28
MD4508C1 (ro) 2018-03-31
AU2012296622A1 (en) 2013-05-09
JP2018065870A (ja) 2018-04-26
LT2744810T (lt) 2016-11-25
BR112014003420A2 (pt) 2017-03-01
MX336627B (es) 2016-01-26
JP2020040972A (ja) 2020-03-19
CN103732594A (zh) 2014-04-16
WO2013025788A1 (en) 2013-02-21
CO6880063A2 (es) 2014-02-28
ZA201400582B (en) 2017-11-29
BR112014003420B1 (pt) 2021-07-20
EA201490208A1 (ru) 2014-06-30
CN110343135A (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
KR20140054068A (ko) 테노포비어 알라펜아미드 헤미푸마레이트
EA031861B1 (ru) Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
AU2014271320B2 (en) Tenofovir alafenamide hemifumarate
HK40018109A (en) Tenofovir alafenamide hemifumarate
NZ620421B2 (en) Tenofovir alafenamide hemifumarate
HK40051818A (en) Tenofovir alafenamide hemifumarate
HK1228372A1 (en) Tenofovir alafenamide hemifumarate
HK1199026B (en) Tenofovir alafenamide hemifumarate
AU2024321551A1 (en) Crystalline form a1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hcl
OA17070A (en) Tenofovir alafenamide hemifumarate.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 34, Claim Number : 1 16, 19 22, 24, 27 39, Period Limitation Text : 119, Comment Text : 9

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 34, Claim Number : 1 16, 19 22, 24, 27 39, Period Limitation Text : 119, Comment Text : 9

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J301 Trial decision

Free format text: TRIAL NUMBER: 2019100000046; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20190104

Effective date: 20220318

Free format text: TRIAL NUMBER: 2019100000041; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20190104

Effective date: 20220318

Free format text: TRIAL NUMBER: 2018100004256; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181221

Effective date: 20220318

Free format text: TRIAL NUMBER: 2018100004255; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181221

Effective date: 20220318

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20220318

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20190104

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2019100000046

Decision date: 20220318

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20190104

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2019100000041

Decision date: 20220318

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20181221

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2018100004256

Decision date: 20220318

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20181221

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2018100004255

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

J301 Trial decision

Free format text: TRIAL NUMBER: 2019100000033; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20190104

Effective date: 20220331

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20220331

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20190104

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2019100000033

J301 Trial decision

Free format text: TRIAL NUMBER: 2019100000045; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20190104

Effective date: 20220401

Free format text: TRIAL NUMBER: 2019100000044; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20190104

Effective date: 20220401

Free format text: TRIAL NUMBER: 2019100000042; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20190104

Effective date: 20220401

Free format text: TRIAL NUMBER: 2019100000040; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20190104

Effective date: 20220401

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20220401

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20190104

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2019100000045

Decision date: 20220401

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20190104

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2019100000044

Decision date: 20220401

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20190104

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2019100000042

Decision date: 20220401

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20190104

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2019100000040

J301 Trial decision

Free format text: TRIAL NUMBER: 2018100004254; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181221

Effective date: 20220413

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20220413

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20190104

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2019100000043

Decision date: 20220413

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20181221

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2018100004254

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

J301 Trial decision

Free format text: TRIAL NUMBER: 2022100002588; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220916

Effective date: 20230316

Free format text: TRIAL NUMBER: 2022100002586; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220916

Effective date: 20230316

Free format text: TRIAL NUMBER: 2022100002142; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20220728

Effective date: 20230316

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20230316

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20220920

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2022100002612

Decision date: 20230316

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20220916

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2022100002588

Decision date: 20230316

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20220916

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2022100002586

Decision date: 20230316

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1612642

Appeal request date: 20220728

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2022100002142

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11